AI assistant
Sending…
EXELIXIS, INC. — Director's Dealing 2025
May 17, 2025
30561_dirs_2025-05-16_da0141ef-b496-4649-86b4-37bd0a4f460b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EXELIXIS, INC. (EXEL)
CIK: 0000939767
Period of Report: 2025-05-15
Reporting Person: PAPADOPOULOS STELIOS (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-15 | Common Stock | M | 20634 | $19.77 | Acquired | 1300050 | Direct |
| 2025-05-15 | Common Stock | S | 20634 | $44.35 | Disposed | 1279416 | Direct |
| 2025-05-15 | Common Stock | M | 15874 | $20.50 | Acquired | 1295290 | Direct |
| 2025-05-15 | Common Stock | S | 15874 | $44.35 | Disposed | 1279416 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-15 | Option (right to buy) | $19.77 | M | 20634 | Disposed | 2026-05-22 | Common Stock (20634) | Direct |
| 2025-05-15 | Option (right to buy) | $20.50 | M | 15874 | Disposed | 2025-05-23 | Common Stock (15874) | Direct |
Footnotes
F1: Includes 18,838 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic
equivalent of one share of Common Stock.
F2: The option, representing the right to purchase a total of 20,634 shares of Common Stock, became fully exercisable on May 23, 2019.
F3: The option, representing the right to purchase a total of 15,874 shares of Common Stock, became fully exercisable on May 24, 2018.
More from EXELIXIS, INC.
Regulatory Filings
2026
May 29
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 21